#United Kingdom #HPV cancer #Outrun Therapeutics #Dundee #E6AP

Outrun Therapeutics Unveils New Treatment Strategy for HPV Positive Head and Neck Cancer

Outrun Therapeutics has revealed its lead program designed to battle HPV positive head and neck cancer, making significant strides in the biotech landscape. This initiative utilizes a unique approach that inhibits the activity of E6AP, a specific E3 ubiquitin ligase that directly influences the levels of tumor suppressor proteins in HPV-related malignancies. The company’s proprietary XL discovery platform, known for profiling a diverse array of E3 ligases in various diseases, has enabled this breakthrough in cancer treatment.

The treatment strategy is not only groundbreaking but has shown promising results during initial in vitro and in vivo testing. Outrun plans to transition this program into clinical trials by 2027. It is estimated that HPV positive cancers account for about 4.5% of various cancer diagnoses globally, with market projections for treatments possibly exceeding $14 billion by 2031. This underscores the importance of Outrun's work in addressing an urgent medical need within an underserved patient demographic.

In a recent announcement, Outrun also introduced its Scientific Advisory Board (SAB), welcoming five esteemed experts in the field of E3 ligase biology and head and neck cancer. This board boasts distinguished individuals like Glenn Hanna from the Dana-Farber Cancer Institute and others who bring a wealth of experience to the table. Their insights will be instrumental as Outrun navigates the complexities of drug development and clinical application for this promising new treatment.

The Significance of E6AP Inhibition

E6AP, an E3 ubiquitin ligase, plays a pivotal role in the regulation of proteins associated with tumor suppression in HPV positive cancers. By targeting and inhibiting E6AP, Outrun seeks to stabilize these critical proteins, potentially leading to better outcomes for patients fighting these cancers. The application of this innovative approach not only enhances the understanding of E3 ligase functions but positions Outrun as a frontrunner in the development of targeted cancer therapies.

The Commitment to Innovation and Patient Care

Dr. Tony Johnson, who currently serves as Board Chair and Interim CEO of Outrun Therapeutics, emphasized the company’s commitment to developing therapeutics that stabilize proteins responsible for combating serious diseases. According to Johnson, the selection of their lead program marks a pivotal point in their journey, especially considering the inadequacies of current treatment options available to patients afflicted by HPV related cancers. This sentiment reflects the ongoing dedication to meaningful innovation in healthcare.

In parallel, Professor Satpal Virdee, the founder and chair of the SAB, expressed optimism regarding the caliber of experts joining the advisory board. Their involvement validates Outrun's innovative technologies and will significantly contribute to refining the clinical strategy necessary for demonstrating efficacy against head and neck cancers triggered by HPV.

Overview of the Scientific Advisory Board

The Scientific Advisory Board features a lineup of experts whose combined experience and insights bolster Outrun's mission.

• - Prof. Glenn Hanna: Specializes in head and neck cancers at the Dana-Farber Cancer Institute, focusing on precision medicine and immunotherapy.
• - Prof. Kevin Harrington: An internationally recognized authority in targeted therapies for head and neck cancer, now leading translational research at the Institute of Cancer Research.
• - Prof. Gigi Lozano: Noted for her research contributions to the p53 tumor suppressor pathway at MD Anderson Cancer Center.
• - Dr. Donald Ogilvie: A drug discovery veteran with extensive experience in oncology, having led initiatives at AstraZeneca and Cancer Research UK.
• - Prof. Martin Scheffner: A leading molecular biologist known for his work on ubiquitin-mediated protein degradation and its implications for HPV-related cancers.

Conclusion

As Outrun Therapeutics continues to forge ahead, the implications of their innovative treatment strategy could reshape the landscape of cancer therapy for HPV positive patients. With a robust advisory team and a clear clinical strategy, they are positioned to make substantial contributions to cancer care and patient outcomes in the coming years. Through their research and development, Outrun not only promises the hope of advanced treatments but also actively engages in addressing the significant health challenges posed by HPV cancers.

The journey of Outrun Therapeutics is one of diligence and dedication, aiming to transform the future of cancer treatment and bring relief to patients in dire need of effective therapeutics.